Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)
• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)
• Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
  di: Nabil Noureddin, et al.
  Pubblicazione: (2024)